Article
Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts.
Oncogene - 12 Jun 2008
Shahrzad S, Shirasawa S, Sasazuki T, Rak J W, Coomber B L
Abstract excerpt
Antiangiogenic therapies are promising approaches to cancer control, but the details of their effects on subsequent tumor progression are not fully understood. Such therapies have the potential to eventually generate extensive amounts of tumor ischemia, and we previously demonstrated that ischemic conditions induce K-ras mutations in cells with deficient mismatch repair (MMR) mechanisms. This suggested that...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.